Cost of Revenue Comparison: Insmed Incorporated vs Alkermes plc

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding cost structures is crucial. This analysis compares the cost of revenue for Insmed Incorporated and Alkermes plc from 2014 to 2023. Over this period, Alkermes consistently reported higher costs, peaking in 2019 with a 693 million USD equivalent, before a significant drop to 218 million USD in 2022. In contrast, Insmed's cost of revenue showed a steady increase, culminating in 2023 with a 66 million USD equivalent, marking a nearly 20-fold increase from its 2015 low. This divergence highlights Alkermes' fluctuating cost management and Insmed's growth trajectory. Such insights are invaluable for investors and stakeholders aiming to gauge financial health and strategic direction.

Key Insights

• Alkermes' cost of revenue decreased by approximately 68% from its 2019 peak.
• Insmed's cost of revenue increased by over 3000% from 2015 to 2023.